115 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
.
Fit-for-purpose
Our platforms can also be utilized to engineer new chemical entities and formulations of those agents that have enhanced properties
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
to manage the unique challenges of cardiovascular and renal disease by modulating, purine metabolism, inflammatory and oxidative state.
Fit-for-purpose
Our … is financially literate and an independent director of the Company for the purpose of NI 52-110 and Rule 10A-3 under the Exchange Act. Mr. Van Damme
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:17pm
hereby appoints the Manager as exclusive agent of the Company for the purpose of selling the Shares of the Company pursuant to this Agreement … or the institution or threatening of any proceeding for that purpose and (v) of the receipt by the Company of any notification with respect to the suspension
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
by modulating purine metabolism, inflammatory and oxidative state.
Fit-for-purpose
Our platforms can also be utilized to engineer new chemical entities
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:13pm
, Ontario, Canada, M5H 4H1.
The purpose of these procedures is to permit Non-Registered Shareholders to direct the voting of the Common Shares … that there are registered Shareholders holding Common Shares that are less than the consolidation ratio. This is not, however, the purpose for which
424B3
h71zw4r hj9hrpgm
13 Jun 24
Prospectus supplement
4:12pm
424B3
3l266
13 Jun 24
Prospectus supplement
4:11pm
424B3
f63n6a01jld wjh4s
13 Jun 24
Prospectus supplement
4:10pm
424B3
6wejnft4rm1q4ss xzgr
13 Jun 24
Prospectus supplement
4:10pm
424B3
l66y8
13 Jun 24
Prospectus supplement
4:08pm
6-K
EX-99.2
s3y3t5
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-10.1
dkoyw0
30 Nov 23
XORTX Announces US ATM Offering
4:04pm
424B5
zojpoj
29 Nov 23
Prospectus supplement for primary offering
9:57pm
6-K
EX-99.2
xut4 wunna5xjbqutsil
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm